Which statement about the PMA pathway for medical devices is true?

Which statement about the PMA pathway for medical devices is true?

• A. PMAs are typically used for high-risk devices to demonstrate safety and effectiveness.
• B. PMAs are only for low-risk devices.
• C. PMAs do not require clinical data.
• D. PMAs are always faster than 510(k).

Answer: (A)

The PMA pathway is the premarket approval route used for the highest-risk medical devices, those classified as Class III. Because these devices pose substantial risk to patients, manufacturers must provide comprehensive evidence of safety and effectiveness, typically including data from well-controlled clinical trials and other robust scientific data, before the device can be marketed. This level of evidence reflects the need to thoroughly characterize benefits and risks given the device’s potential impact on health. This is why the statement is true: PMAs are specifically for high-risk devices to demonstrate safety and effectiveness. They are not intended for low-risk devices—that category usually goes through the 510(k) pathway, which relies on substantial equivalence to a legally marketed predicate and generally requires less intensive clinical data. PMAs do require clinical data, so the idea that they do not is incorrect. And PMAs are not always faster than 510(k); in fact, they are typically slower due to the more extensive data and longer FDA review process involved.

The PMA pathway is the premarket approval route used for the highest-risk medical devices, those classified as Class III. Because these devices pose substantial risk to patients, manufacturers must provide comprehensive evidence of safety and effectiveness, typically including data from well-controlled clinical trials and other robust scientific data, before the device can be marketed. This level of evidence reflects the need to thoroughly characterize benefits and risks given the device’s potential impact on health.

This is why the statement is true: PMAs are specifically for high-risk devices to demonstrate safety and effectiveness. They are not intended for low-risk devices—that category usually goes through the 510(k) pathway, which relies on substantial equivalence to a legally marketed predicate and generally requires less intensive clinical data. PMAs do require clinical data, so the idea that they do not is incorrect. And PMAs are not always faster than 510(k); in fact, they are typically slower due to the more extensive data and longer FDA review process involved.